Histamine dihydrochloride and low-dose interleukin-2 has antileukemic efficacy in NPM1-mutated and myelomonocytic/monocytic acute myeloid leukemia
Malin S. Nilsson,
Michael Fiegl,
Wolfgang Hiddemann,
Wolfgang R. Sperr,
Fredrik B. Thorén,
Anna Martner,
Kristoffer Hellstrand
Affiliations
Malin S. Nilsson
TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg
Michael Fiegl
Internal Medicine, Privatklinik Hochrum, Rum
Wolfgang Hiddemann
Department of Internal Medicine III, University Hospital of the Ludwig-Maximilians-University Munich, Munich
Wolfgang R. Sperr
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna
Fredrik B. Thorén
TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg
Anna Martner
TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg
Kristoffer Hellstrand
TIMM Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sweden; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg
